Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective-Reference-Cited by-同舟云学术

Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective

Published:2024-10 Issue: Volume:196 Page:107950
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Grit Geeske F^ORCID,van Geffen Esmée,Malmberg Ruben^ORCID,van Leeuwen Roelof,Böhringer Stefan,JM Smit Hans,Brocken Pepijn^ORCID,FH Eijsink Job,Dronkers Esther^ORCID,Gal Pim,Jaarsma Eva^ORCID,JHM van Drie-Pierik Regine,MP Eldering-Heldens Anne,Machteld Wymenga AN,GM Mol Peter,Zwaveling Juliëtte,Hilarius Doranne

Funder

Horizon Europe

Publisher

Elsevier BV

Reference34 articles.

1. World Health Organisation, Cancer Today, (2020). https://gco.iarc.fr/today/home (accessed November 2, 2023).

2. American Cancer Society, Key Statistics for Lung Cancer, (2023). https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html (accessed November 2, 2023).

3. A review about pembrolizumab in first-line treatment of advanced NSCLC: Focus on KEYNOTE studies;Qu;Cancer Manag. Res.,2020

4. M. Reck, D. Rodríguez-Abreu, A.G. Robinson, R. Hui, Tibor Csoszi, A. Fulop, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O’brien, S. Rao, K. Hotta, T.A. Leal, J.W. Riess, E. Jensen, B. Zhao, M.C. Pietanza, J.R. Brahmer, Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ‡ 50%, J. Clin. Oncol. 39 (2021) 2339–2349. Doi: 10.1200/JCO.21.00174.

5. European Medicines Agency (EMA), Summary of product characteristics KEYTRUDA, n.d. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf (accessed October 6, 2023).